Alvotech Suffers Delay On Higher-Strength Adalimumab In US
Facility Inspection Obstacles Lead FDA To Defer Action On Humira Biosimilar
Executive Summary
Alvotech has suffered a setback in its attempt to gain the first US FDA approval for a higher-strength biosimilar adalimumab rival to Humira, after obstacles preventing facility inspections led the agency to defer action on the firm’s AVT02 candidate.
You may also be interested in...
Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars
Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.
Samsung Bioepis Aims To Compete On Higher-Strength Humira In US
Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.
US Biosimilar Approvals In 2021 Were Few But Included Many Firsts
While US biosimilar approvals have been somewhat thin on the ground in 2021 – with the pandemic driving inspection-related delays for multiple products – there were nevertheless several firsts this year, including the first two interchangeables and the first ophthalmic biosimilar.